Search results for: 'power 1'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping diagnostics, therapeutics, and clinical workflows across infectious diseases, women’s health, metabolic disorders, neurodegeneration, oncology, rare diseases, and musculoskeletal care. It hi...

There have been increasing incidences of rare ophthalmic diseases (e.g., retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis) and prevalent diseases (e.g., age-related macular degeneration [AMD], geographic atrophy). While clinicians have used small molecules as the conventional therapeutic modality to manage these diseases, the urg...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping therapeutics, diagnostics, and drug delivery across infectious diseases, oncology, rare genetic disorders, autoimmune conditions, cardiovascular disease, pulmonary fibrosis, neurodegeneratio...

As the industry continues to innovate across novel small- and large-molecule therapies, including RNA-targeted small molecules, cell and gene therapies, and mRNA therapies, pharma sponsors increasingly rely on partners for technology access, database generation and analysis, and preclinical and clinical research.These disruptions continue to drive ...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...

08 Sep 2025  |  Global  |  Market Research

Growth Opportunities in Global Protein and Peptide Therapeutics, Forecast to 2030

Cross-Therapeutic Expansion is Driving Transformational Growth Fueled by Novel Formats and Smarter Delivery

Infographics

×

The protein and peptide therapeutics industry is undergoing a profound transformation, driven by next-generation biologics, including multi-specific antibodies, antibody-drug conjugates (ADCs), and GLP-1 treatments. These advances are intensifying competition, while the patent expiries of blockbuster antibodies are accelerating the entry of biosimi...

31 Jul 2025  |  Global  |  Technology Research

Growth Opportunities in RNA Therapeutics

Broad Applications Drive Growth in RNA Therapeutics

Infographics

×

The report analyzes clinical trial activity across RNA therapeutic classes, including small interfering RNA (siRNA), messenger RNA (mRNA), antisense oligonucleotides (ASO), aptamers, micro RNA (miRNA), self-amplifying RNA (saRNA), small-activating RNA (RNAa), and circular RNA (cirRNA). It highlights key players in each segment and their role in adv...

The global pharmaceutical market is projected to reach approximately $1.72 trillion in 2026, with large molecules driving most incremental growth while small molecules remain the sector’s cash flow base. The current growth cycle concentrates on cardiometabolic and oncology, led by GLP-1 platforms and antibody–drug conjugates (ADCs). Competitive adv...

The study presents an in-depth exploration of novel functional ingredients designed to enhance mental and emotional well-being, identifying the overall drivers of growth, technological change, and market opportunities through 2030. Mental health disorders continue to present a serious global challenge, with anxiety and depression affecting more tha...